Revenue climbed 41%, while TransMedics' net income fell to $17.1 million.
TransMedics reported Q3 2026 revenue of $203.0 million, up 41% YoY, with product and service revenue growth of 29% and 60% respectively. Net income fell to $17.1 million, while adjusted net income was $18.9 million. The company raised its full-year 2026 revenue guidance to $764-$774 million, including $14 million from PAD Aviation. Key developments include FDA approvals for clinical trials and EU expansion.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise provide a fresh catalyst that could move the stock in the short term.
Market read
First‑report earnings and guidance update for a listed biotech, offering a clear trading signal.
What to watch
Net income decline and operating margin compression may limit enthusiasm.
Background
TransMedics is a Nasdaq‑listed medical‑device company focused on organ perfusion technologies.
Ticker impact
TransMedics reported Q3 2026 results with 41% revenue growth and raised full‑year revenue guidance.
likely upward pressure as investors price in higher revenue outlook.
Revenue beat and guidance raise are fresh primary data; market typically reacts positively to such earnings surprises.
Market effects
Positive signal for the organ‑preservation and transplant technology sector.
May boost biotech sentiment in the U.S. market.
Limited to niche medical device space.
Counterpoint
Guidance relies on upcoming trial enrollments; execution risk could temper upside.
Key entities
- CompanyTransMedics Group, Inc.
Medical‑device firm reporting Q3 2026 results.
